A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
B G Feagan(Western University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Séverine Vermeire(KU Leuven), Ursula Seidler(Medizinische Hochschule Hannover), Rajiv Mehta(Amrita Institute of Medical Sciences and Research Centre), X Liu(Gilead Sciences (United States)), William J. Sandborn(University of San Diego), G Rogler(University Hospital Zurich), J. McNally(Gilead Sciences (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Chohee Yun(Gilead Sciences (United States)), Sally Zhao(Gilead Sciences (United States)), T Ritter, H Kim(Kyung Hee University Dental Hospital), Edward V. Loftus(Mayo Clinic), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Toshihumi Hibi(Kitasato Institute Hospital), Makiko Watanabe(The University of Texas at Austin), F Seibold, Chantal Tasset(Galapagos (Belgium)), R. Besuyen(Galapagos (Belgium)), Ian Beales(University of East Anglia)
Cited by 8
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k